Patterns of Care and Data Quality in a National Registry of Black and White Patients with Merkel Cell Carcinoma

被引:2
|
作者
Rattani, Abbas [1 ]
Gaskins, Jeremy [2 ]
McKenzie, Grant [3 ]
Scharf, Virginia Kate [4 ]
Broman, Kristy [5 ]
Pisu, Maria [6 ]
Holder, Ashley [5 ]
Dunlap, Neal [3 ]
Schwartz, David [7 ]
Yusuf, Mehran B. [8 ]
机构
[1] Tufts Univ, Dept Radiat Oncol, Med Ctr, Boston, MA 02111 USA
[2] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Brown Canc Ctr, Dept Radiat Oncol, Sch Med, Louisville, KY 40202 USA
[4] Univ Louisville, Sch Med, Louisville, KY 40202 USA
[5] Univ Alabama Birmingham, Dept Surg, Div Surg Oncol, Birmingham, AL 35294 USA
[6] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[7] Univ Tennessee, Dept Radiat Oncol, Hlth Sci Ctr, Memphis, TN 38163 USA
[8] Univ Alabama Birmingham, Dept Radiat Oncol, ONeal Comprehens Canc Ctr, Sch Med, Birmingham, AL 35294 USA
关键词
Merkel Cell Carcinoma; race; epidemiology; SURVIVAL; EPIDEMIOLOGY; CANCER; RACE;
D O I
10.3390/cancers14205059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Merkel Cell Carcinoma is a rare skin cancer most commonly affecting White patients. Less is known for Black patients. We aimed to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. Findings from this work aim to impact patient and provider awareness to further equitable access to optimal cancer care across the spectrum from diagnosis and treatment to post-therapy surveillance for patients with Merkel Cell Carcinoma. Merkel Cell Carcinoma (MCC) is a rare cancer most commonly affecting White patients; less is known for Black patients. We aim to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. We conducted a retrospective cohort analysis between 2006-2017 via the National Cancer Database of Black and White MCC patients with and without known staging information. Multivariable logistic, proportional odds logistic, and baseline category logistic regression models were used for our primary endpoint. Multivariable Cox regression was used to interrogate overall survival. Multiple imputation was used to mitigate missing data bias. 34,503 patients with MCC were included (2566 Black patients). Black patients were younger (median age 52 vs. 72, p < 0.0001), had higher rates of immunosuppression (28% vs. 14%, p = 0.0062), and were more likely to be diagnosed at a higher stage (proportional OR = 1.41, 95% CI 1.25-1.59). No differences were noted by race across receipt of definitive resection (DR), though Black patients did have longer time from diagnosis to DR. Black patients were less likely to receive adjuvant radiation. Black patients were more likely to have missing cancer stage (OR = 1.69, CI 1.52-1.88). Black patients had decreased adjusted risk of mortality (HR 0.73, 0.65-0.81). Given the importance of registry analyses for rare cancers, efforts are needed to ensure complete data coding. Paramount to ensuring equitable access to optimal care for all is the recognition that MCC can occur in Black patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Merkel cell carcinoma occurring in a black woman: a case report
    Kadiri S.
    Aissa A.
    Berhili S.
    Khmou M.
    Elmajjaoui S.
    Kebdani T.
    El Khannoussi B.
    Elkacemi H.
    Benjaafar N.
    Journal of Medical Case Reports, 11 (1) : 1 - 5
  • [42] Predictors of palliative care receipt in Merkel cell carcinoma
    Marani, Melika
    Tripathi, Raghav
    Scott, Jeffrey F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 403 - 404
  • [43] Small cell carcinoma of the prostate: National patterns of care and outcomes.
    Horne, Zachary D.
    Smith, Ryan P.
    Beriwal, Sushil
    Kalash, Ronny
    Shinde, Ashwin
    Glaser, Scott
    Fuhrer, Russell
    Wegner, Rodney E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] Second neoplasms in patients with merkel cell carcinoma
    Brenner, B
    Sulkes, A
    Rakowsky, E
    Feinmesser, M
    Yukelson, A
    Bar-Haim, F
    Katz, A
    Idelevich, E
    Neuman, A
    Barhana, M
    Fenig, E
    CANCER, 2001, 91 (07) : 1358 - 1362
  • [45] Cabozantinib in Patients with Advanced Merkel Cell Carcinoma
    Rabinowits, Guilherme
    Lezcano, Cecilia
    Catalano, Paul J.
    McHugh, Patricia
    Becker, Hailey
    Reilly, Megan M.
    Huang, Julian
    Tyagi, Ayushi
    Thakuria, Manisha
    Bresler, Scott C.
    Sholl, Lynette M.
    Shapiro, Geoffrey I.
    Haddad, Robert
    DeCaprio, James A.
    ONCOLOGIST, 2018, 23 (07): : 814 - 821
  • [46] Reccomendations for the treatment of patients with Merkel cell carcinoma
    Olga, Blatnik
    Marko, Boc
    Tomi, Bremec
    Marko, Hocevar
    Katarina, Karner
    Bostjan, Luzar
    Janja, Ocvirk
    Barbara, Peric
    Joze, Pizem
    Martina, Rebersek
    Primoz, Strojan
    ONKOLOGIJA, 2019, 23 (01) : 96 - 103
  • [47] Current management of patients with Merkel cell carcinoma
    Brady, MS
    DERMATOLOGIC SURGERY, 2004, 30 (02) : 321 - 325
  • [48] Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma
    Schmocker, Ryan K.
    Nodit, Laurentia
    Ward, Andrew J.
    Lewis, James M.
    McLoughlin, James M.
    Enomoto, Laura M.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (01) : 464 - 473
  • [49] Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma
    Reisinger, Diane M.
    Shiffer, Jeffrey D.
    Cognetta, Armand B., Jr.
    Chang, Yuan
    Moore, Patrick S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (03) : 400 - 403
  • [50] Expression patterns of tight junction proteins in Merkel cell carcinoma
    Haass, NK
    Houdek, P
    Wladykowski, E
    Moll, I
    Brandner, JM
    MERKEL CELL: STRUCTURE-DEVELOPMENT-FUNCTION-CANCEROGENESIS, 2003, : 223 - 226